The Record...
I planned to send Sharon information on ratings from this database, but I'll wait on that. First, I think she will find the nomenclature data comprehensive. She might also need the extensive pharmacology information. I'll just get the entire record.
The first part of the record in Adis R&D Insight includes basic drug data, such as the drug name, company information, and synonyms for the drug as in File 445, IMS R&D Focus, and File 128, Pharmaprojects.
Note that the brand name is in a separate field similar to IMS's structure. The lab code and other names are listed under synonyms in Adis as they are in Pharmaprojects.
This database includes not only the EPhMRA ATC Code (Anatomical Therapeutic Class Codes) but also the ATC Code from the World Health Organization (WHO) making it an important database for healthcare institutions.
Note: In order to give you supplemental information (tips, learn more comments) about the Dialog record, we have had to add spaces between some of the fields. Print out the complete record for File 107 to have a concise duplicate of the Dialog record you will retrieve online. You can compare it to the parts of the record we will highlight later in the lesson.
Here are a few things Sharon might want to see from this part of this record.
- Drug/product name: Adis R&D Insight provides a broad range of alternative product nomenclature with drug name, brand name, synonym, chemical name, and CAS® Registry Number. Tip 4-1
- Company name: The company name is a broad label including the originator company, parent company, other companies and licensee company. The file indexes the parent company name for originators not licensees. Tip 4-2
- Development status: The developmental status gives a history of the drug's progress through phases, registration, and launch in different countries, with indications included.
Unlike the two databases we just reviewed, File 107 does not have patent information.
Review the bibliographic part of the record and then go to the next page.
5/9/1 DIALOG(R)File 107: Adis R&D Insight (c) 2007 Adis Data Information BV. All rights reserved. 00240128 012103 Drug Name: Vatalanib Record Revision Date: 20061229 Synonyms: CGP 79787; PTK 787; PTK/ZK; PTK787; ZK 222584 Chemical Name: 1-(p-chloroanilino)-4-(4-pyridylmethyl)phthalazine Molecular Formula: C20H15ClN4 CAS Registry Number: 212141-54-3 WHO ATC Code: L01 - Antineoplastic Agents; S01X - Other Ophthalmologicals Tip 4-3 EPHMRA ATC Code: L1 - Antineoplastics; S1X - Other Ophthalmologicals Mechanism of Action: Tyrosine kinase inhibitors; Protein kinase inhibitors; Protein kinase modulators; Phosphotransferase (Alcohol Group Acceptor) inhibitors; Phosphotransferase (Alcohol Group Acceptor) modulators; Kinase inhibitors; Kinase modulators; Transferase inhibitors; Transferase modulators; Enzyme inhibitors; Enzyme modulators; Vascular endothelial growth factor antagonists; Angiogenic protein inhibitors; Protein inhibitors; Peptide antagonists; Growth factor antagonists; Intercellular signalling peptide and protein inhibitors; Protein modulators Originator Company: Bayer Schering Pharma (Germany); Novartis (Switzerland); M. D. Anderson Cancer Center (USA); Novartis (USA) Parent Company: Bayer; M. D. Anderson Cancer Center; Novartis Licensee: Bayer Schering Pharma; Novartis Highest Phase: Phase III Tip 4-4 Development Status: Phase III, Switzerland, Colorectal cancer Phase III, USA, Colorectal cancer Phase II, Switzerland, Age-related macular degeneration Phase II, Italy, Glioblastoma Phase II, Netherlands, Glioblastoma Phase II, France, Non-small cell lung cancer Phase II, Germany, Non-small cell lung cancer Phase II, Switzerland, Solid tumours Phase II, USA , Solid tumours Phase I, Germany, Colorectal cancer Phase I, Germany, Glioblastoma Phase I, Germany, Ovarian cancer Phase I, Germany, Renal cancer Phase I, Switzerland, Renal cancer Preclinical, USA, Multiple myeloma
Go to the next page to learn more about the Pharmacology information contained in this record.
